EYPT
$13.23-0.56 (-4.06%)
EyePoint, Inc.
Recent News
How The EyePoint (EYPT) Story Is Shifting With Phase 3 DME And Duravyu In Focus
Analysts covering EyePoint have refreshed their models, with bullish price targets now clustered in the US$29 to US$35 range. These revisions are being linked to more detailed valuation work on the late stage pipeline, especially the Phase 3 diabetic macular edema program, and ongoing tracking of Duravyu execution after the Q4 report. As you read on, you will see how these moving pieces shape the evolving story and what to watch to stay on top of the narrative. Stay updated as the Fair Value...
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
March 20 () - EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading false or misleading information about EyePoint and its lead experimental eye drug. The complaint was filed in Middlesex County Superior Court for the Commonwealth of Massachusetts.
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.